Evidence map›Paper›PMID 37914764›Full record

ArticleScientific reports2023

Sinonasal mucosal melanoma treatment response assessment to immune checkpoint inhibitors using hybrid positron emission tomography imaging.

Alexander Maurer, Nathalie A Gstrein, Florentia Dimitriou, Thomas Sartoretti, Jan A Schaab, Esmée L Looman, Panagiotis Balermpas, Niels J Rupp, Sandra N Freiberger, Michael B Soyka and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Alexander Maurer *Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Nathalie A Gstrein *Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Frauenklinikstrasse 24, 8091, Zurich, Switzerland.
Florentia DimitriouDepartment of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Thomas SartorettiDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Jan A SchaabDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Esmée L LoomanDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Panagiotis BalermpasDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Niels J RuppDepartment of Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Sandra N FreibergerDepartment of Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Michael B SoykaDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Frauenklinikstrasse 24, 8091, Zurich, Switzerland.
David HolzmannDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Frauenklinikstrasse 24, 8091, Zurich, Switzerland.
Tina MautheDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Frauenklinikstrasse 24, 8091, Zurich, Switzerland.
Simon A MuellerDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Frauenklinikstrasse 24, 8091, Zurich, Switzerland.
Stephan Beintner-SkawranDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Michael MesserliDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
David KenkelDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Martin W HuellnerDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-4849-3292
Christian M MeerweinDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Frauenklinikstrasse 24, 8091, Zurich, Switzerland. christian.meerwein@usz.ch.
University of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this retrospective study was to investigate response of sinonasal mucosal melanoma (SMM) patients to treatment with immune checkpoint inhibitors (ICI), using hybrid PET imaging. Fifteen SMM patients underwent hybrid PET imaging before and three months after initiation of ICI. The disease-specific survival (DSS) was calculated. Quantitative PET parameters of the primary tumor and their association with DSS and therapy response were investigated. Nine of the fifteen (60%) patients responded to ICI therapy. Patients with therapy response depicted on hybrid PET imaging had better DSS than those without (p = 0.0058). Quantitative PET parameters of the initial PET harbored no association with DSS or therapy response. However, these findings lack of sufficient statistical power and must be interpreted with caution. The first restaging PET-imaging after ICI initiation can help stratify patients with regard to DSS.

Indexed as

MelanomaParanasal Sinus NeoplasmsFluorodeoxyglucose F18HumansImmune Checkpoint InhibitorsPositron-Emission TomographyPositron Emission Tomography Computed TomographyRetrospective StudiesFluorodeoxyglucose F18Immune Checkpoint Inhibitors

Identifiers

PMID37914764
PMCPMC10620201
OpenAlexW4388126996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.